🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery
OpenAI-backed Chai Discovery hit $4B valuation as pharma AI tools deals surge
Chai Discovery, just two years old and OpenAI-backed, raised $400M in Series C funding at a $4B valuation and was central to four major AI-pharma tools deals announced at the JPM conference in January 2026. This marks a structural shift in BioAI: pharma companies are now actively paying for AI tools at scale rather than waiting for AI startups to build their own drug pipelines. The deal dynamic signals a maturation point where validated AI tooling can command enterprise pharma contracts directly.